Drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-dependent calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-dependent calcium channel inhibitors containing the above compounds as the active ingredient,

 $\begin{array}{c|c} N & \\ \hline D & \\ \hline CH_2 \\ \hline \\ \hline n & \\ \hline B \\ \hline X - A(1) \end{array}$

(in the formula, each symbol has the following meaning: B: phenylene, a nitrogen-containing, divalent, saturated ring group, or a monocyclic, divalent heteroaromatic ring group which may be substituted with Alk, $X: -NR^1-CR^2R^3-$, $-CR^2R^3-NR^1-$, $-NR^1-SO_2-$, $-SO_2-NR^1-$ or

X: $-NR^{1}-CR^{2}R^{3}-$, $-CR^{2}R^{3}-NR^{1}-$, $-NR^{1}-SO_{2} -SO_{2}-NR^{1}-$ or $-CR^{4}=CR^{5}-$, and

A: benzene ring which may have one or more substituents; mono-, di- or tricyclic fused heteroaryl which may have one or more substituents; cycloalkyl which may have one or more substituents; a nitrogen-containing, saturated ring group which may have one or more substituents; lower alkenyl which may have one or more substituents; lower alkynyl which may have one or more substituents; or Alk which may have one or more substituents; or Alk which may have one or more substituents).